Intrinsic Value of S&P & Nasdaq Contact Us

Insulet Corporation PODD NASDAQ

NASDAQ Global Select • Healthcare • Medical - Devices • US • USD

SharesGrow Score
74/100
4/7 Pass
SharesGrow Intrinsic Value
$321.45
+59.5%
Analyst Price Target
$357.25
+77.3%

Insulet Corporation (PODD) generated $569.3M in operating cash flow for fiscal year 2025. After capital expenditures of $191.6M, free cash flow was $377.7M.

Free cash flow margin was 13.9% of revenue. Cash conversion ratio was 2.3x, indicating earnings are backed by cash.

The company returned $59.6M in share buybacks to shareholders during the period.

Criteria supported by this page:

  • HEALTH (67/100, Partial) — cash generation is adequate but may not fully cover debt in stressed conditions
  • MOAT (80/100, Pass) — $377.7M (13.9% FCF margin) supports a durable competitive advantage
  • INCOME (45/100) — Cash conversion ratio was 2.3x confirms earnings are backed by real cash flow

Overall SharesGrow Score: 74/100 with 4/7 criteria passed.

SharesGrow 7-Criteria Score
74/100
SG Score
View full scorecard →
~
VALUE
42/100
Price-to-Earnings & upside
→ Valuation
FUTURE
85/100
Analyst consensus
→ Forecast
PAST
100/100
→ Income
~
HEALTH
67/100
Debt-to-Equity & liquidity
Proven by this page
MOAT
80/100
Proven by this page
GROWTH
100/100
→ Income
~
INCOME
45/100
→ Income
Insulet Corporation Cash Flow History
Metric TTM FY2025 FY2024 FY2023 FY2022
Operating Cash Flow $569.3M$569.3M$430.3M$145.7M$119M
Capital Expenditure $-191.6M$-191.6M$-124.9M$-75.6M$-157.3M
Free Cash Flow $377.7M$377.7M$305.4M$36.5M$-38.3M
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
Send us a message